Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients.

NCT00318552 · clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
160
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Pfizer